Merck & Co., Inc. (MRK) stock
MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 9/30239% above fair value
$143.37−1.09 (-0.75%)
Close on Nov 17, 2026Market cap $353.72BP/E 114.7Yield 2.29%
Merck net income
Net income is the profit left for shareholders after every expense, interest and tax.
Merck's net income for the twelve months ending Jun 30, 2026 was $3.17B, down 80.7% year over year. For fiscal 2025 it was $18.25B, up 6.6% from the year before. Over ten years it grew 15.2% a year on average. The highest annual figure on record is $18.25B in fiscal 2025.
Annual net income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $18.25B | +6.6% |
| FY2024 | Dec 31, 2024 | $17.12B | +4589.6% |
| FY2023 | Dec 31, 2023 | $365.00M | -97.5% |
| FY2022 | Dec 31, 2022 | $14.52B | +11.3% |
| FY2021 | Dec 31, 2021 | $13.05B | +84.6% |
| FY2020 | Dec 31, 2020 | $7.07B | -28.2% |
| FY2019 | Dec 31, 2019 | $9.84B | +58.2% |
| FY2018 | Dec 31, 2018 | $6.22B | +159.8% |
| FY2017 | Dec 31, 2017 | $2.39B | -38.9% |
| FY2016 | Dec 31, 2016 | $3.92B | -11.8% |
| FY2015 | Dec 31, 2015 | $4.44B | -62.7% |
| FY2014 | Dec 31, 2014 | $11.92B | +170.7% |
| FY2013 | Dec 31, 2013 | $4.40B | -28.6% |
| FY2012 | Dec 31, 2012 | $6.17B | -1.7% |
| FY2011 | Dec 31, 2011 | $6.27B | +628.5% |
| FY2010 | Dec 31, 2010 | $861.00M | -93.3% |
| FY2009 | Dec 31, 2009 | $12.90B | +65.2% |
| FY2008 | Dec 31, 2008 | $7.81B | +138.4% |
| FY2007 | Dec 31, 2007 | $3.28B | – |
Quarterly net income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$1.34B | -130.2% |
| Q1 FY2026 | Mar 31, 2026 | -$4.24B | -183.5% |
| Q4 FY2025 | Dec 31, 2025 | $2.96B | -20.8% |
| Q3 FY2025 | Sep 30, 2025 | $5.79B | +83.2% |
| Q2 FY2025 | Jun 30, 2025 | $4.43B | -18.8% |
| Q1 FY2025 | Mar 31, 2025 | $5.08B | +6.7% |
| Q4 FY2024 | Dec 31, 2024 | $3.74B | – |
| Q3 FY2024 | Sep 30, 2024 | $3.16B | -33.5% |
| Q2 FY2024 | Jun 30, 2024 | $5.46B | – |
| Q1 FY2024 | Mar 31, 2024 | $4.76B | +68.8% |
| Q4 FY2023 | Dec 31, 2023 | -$1.23B | -140.6% |
| Q3 FY2023 | Sep 30, 2023 | $4.75B | +46.1% |
| Q2 FY2023 | Jun 30, 2023 | -$5.98B | -251.5% |
| Q1 FY2023 | Mar 31, 2023 | $2.82B | -34.5% |
| Q4 FY2022 | Dec 31, 2022 | $3.02B | -19.7% |
| Q3 FY2022 | Sep 30, 2022 | $3.25B | -28.9% |
| Q2 FY2022 | Jun 30, 2022 | $3.94B | +155.3% |
| Q1 FY2022 | Mar 31, 2022 | $4.31B | +35.6% |
| Q4 FY2021 | Dec 31, 2021 | $3.76B | – |
| Q3 FY2021 | Sep 30, 2021 | $4.57B | +55.3% |
| Q2 FY2021 | Jun 30, 2021 | $1.55B | -48.5% |
| Q1 FY2021 | Mar 31, 2021 | $3.18B | -1.2% |
| Q4 FY2020 | Dec 31, 2020 | -$2.09B | -188.9% |
| Q3 FY2020 | Sep 30, 2020 | $2.94B | +54.7% |
| Q2 FY2020 | Jun 30, 2020 | $3.00B | +12.4% |
| Q1 FY2020 | Mar 31, 2020 | $3.22B | +10.4% |
| Q4 FY2019 | Dec 31, 2019 | $2.36B | +29.0% |
| Q3 FY2019 | Sep 30, 2019 | $1.90B | -2.5% |
| Q2 FY2019 | Jun 30, 2019 | $2.67B | +56.4% |
| Q1 FY2019 | Mar 31, 2019 | $2.92B | +296.1% |
| Q4 FY2018 | Dec 31, 2018 | $1.83B | – |
| Q3 FY2018 | Sep 30, 2018 | $1.95B | – |
| Q2 FY2018 | Jun 30, 2018 | $1.71B | -12.3% |
| Q1 FY2018 | Mar 31, 2018 | $736.00M | -52.5% |
| Q4 FY2017 | Dec 31, 2017 | -$1.05B | – |
| Q3 FY2017 | Sep 30, 2017 | -$56.00M | -102.6% |
| Q2 FY2017 | Jun 30, 2017 | $1.95B | – |
| Q1 FY2017 | Mar 31, 2017 | $1.55B | – |
| Q4 FY2016 | Dec 31, 2016 | -$595.00M | – |
| Q3 FY2016 | Sep 30, 2016 | $2.18B | – |
See a number that looks wrong?